Correlation between Obesity and Inflammation in Cardiovascular Diseases—Evaluation of Leptin and Inflammatory Cytokines


Obesity, an important risk factor for cardiovascular disease (CVD), is currently viewed as a pro-inflammatory state with an increase in the expression of inflammatory cytokines including Tumor Necrosis Factor-α (TNF-alpha) and Interleukin-6 (IL-6) along with the increased secretion of leptin. Serum leptin was estimated in 150 CVD patients (belonging to the age group of 35 - 75 years) of different Body Mass Index (BMI) and its correlation to various biochemical parameters including lipids, glucose and CRP was analyzed to study the association of leptin with CVD. Further to understand the relationship between obesity, inflammation and CVD, serum leptin, TNF-alpha, IL-6 was evaluated in 50 CVD and 50 non-CVD subjects. Results were presented as mean ± SD. A distinct correlation between leptin, TNF-alpha, IL-6 and BMI was observed and these cytokines were elevated in CVD subjects. The protein expression of the monomeric form of CRP which is known to be expressed in pathological condition was found to be highly expressed in serum of CVD subjects. Further, to substantiate the role of inflammation in obesity related CVD, different concentrations of leptin were added to Peripheral Blood Mononuclear Cells (PBMC) isolated from twenty healthy volunteers of different BMI and the gene expression of TNF-alpha, IL-6 and Ob-Rb were studied. A significant increase in the level of these cytokines was observed with increasing leptin concentration. The results obtained from the present analysis suggest that inflammation may be a crucial factor involved in obesity associated CVD.

Share and Cite:

R. Raskin Erusan, D. Nalini, G. Manohar and R. Malathi, "Correlation between Obesity and Inflammation in Cardiovascular Diseases—Evaluation of Leptin and Inflammatory Cytokines," Open Journal of Endocrine and Metabolic Diseases, Vol. 2 No. 2, 2012, pp. 7-15. doi: 10.4236/ojemd.2012.22002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold and J. M. Friedman, “Positional Cloning of the Mouse Obese Gene and Its Human Homologue,” Nature, Vol. 372, No. 6505, 1994, pp. 425-432. doi:10.1038/372425a0
[2] C. Popa, M. G. Netea, T. Radstake, P. L. Van Riel, P. Barrera and J. W. M. Van Der Meer, “Markers of Inflammation Are Negatively Correlated with Serum Leptin in Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Vol. 64, No. 8, 2005, pp. 1195-1198.
[3] G. Matarese, S. Moschos and C. S. Mantzoros, “Leptin in Immunology,” Journal of Immunology, Vol. 174, No. 6, 2005, pp. 3137-3142.
[4] M. R. Ram and R. Malathi, “Possible Correlation of Leptin with Body Fat Distribution and Adiposity: Evaluation of Serum Leptin in South Indian Population,” Reproductive Medicine and Biology, Vol. 6, No. 2, 2007, pp. 117-125. doi:10.1111/j.1447-0578.2007.00174.x
[5] S. Loffreda, S. Q. Yang, H. Z. Lin, C. L. Karp, M. L. Brengman, D. J. Wang, A. S. Klein, G. B. Bulkley, C. Bao, P. W. Noble, M. D. Lane and A. M. Diehl, “Leptin Regulates Proinflammatory Immune Responses,” The Journal of the Federation of American Society for Experimental Biology, Vol. 12, No. 1, 1998, pp. 57-65.
[6] J. V. Castell, M. J. Gomez-Lechon, M. David, R. Fabra, R. Trullenque and P. C. Heinrich, “Acute Phase Response of Human Hepatocytes: Regulation of Acute Phase Protein Synthesis by Interleukin-6,” Hepatology, Vol. 12, No. 5, 1990, pp. 1179-1186. doi:10.1002/hep.1840120517
[7] P. Libby and P. M. Ridker, “Inflammation and Atherosclerosis: Role of C-Reactive Protein in Risk Assessment,” American Journal of Medicine, Vol. 116, No. 6, 2004, pp. 9-16. doi:10.1016/j.amjmed.2004.02.006
[8] M. B. Pepys and G. M. Hirschfield, “C-Reactive Protein and Its Role in the Pathogenesis of Myocardial Infarction,” Italian Heart Journal, Vol. 2, No. 11, 2001, pp. 804-806.
[9] L. Dubey, H.-S. Zeng, H.-J. Wang and R.-Y. Liu, “Potential Role of Adipocytokine Leptin in Acute Coronary Syndrome,” Asian Cardiovascular and Thoracic Annals, Vol. 16, No. 2, 2008, pp. 124-128
[10] H. D. Sesso, J. E. Buring, N. Rifai, G. J. Blake, J. M. Gaziano and P. M. Ridker, “C-Reactive Protein and the Risk of Developing Hypertension,” Journal of American Medical Association, Vol. 290, No. 22, 2003, pp. 2945-2951. doi:10.1001/jama.290.22.2945
[11] L. A. Viikari, R. K. Huupponen, J. S. A. Viikari, J. Marniemi, C. Eklund, M. Hurme, T. Lehtimaki, M. Kivimaki and O. T. Raitakari, “Relationship between Leptin and CReactive Protein in Young Finnish Adults,” The Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 12, 2007, pp. 4753-4758. doi:10.1210/jc.2007-0103
[12] P. Trinder, “Determination of Blood Glucose Using 4Aminophenazone,” J Clin Pathol, Vol. 22, No. 2, 1959, p. 246. doi:10.1136/jcp.22.2.246-b
[13] J. L. Beamount, L. A. Crison, G. R. Coope, Z. Feifar, D. S. Frederickson and T. Strasser, “Classification of Hyperlipidemias and Hyperlipoproteinemias,” Standard Methods of Clinical Chemistry, Academic Press, New York, 1972, p. 9.
[14] D. N. Holvey, “The Merck Manual of Diagnosis and Therapy,” Merck Inc., Rahway, 1972.
[15] T. G. Cole, S. G. Klotzsch and J. Mc Namara, “Measurement of Triglyceride Concentration. Handbook of Lipoprotein Testing,” AACC Press, Washington DC, 1997.
[16] Z. X. Wang and T. Nakayama, “Inflammation, A Link between Obesity and Cardiovascular Disease,” Mediators of Inflammation, Vol. 2010, 2010, pp. 1-17. doi:10.1155/2010/535918
[17] W. A. Banks, A. B. Coon, S. M. Robinson, A. Moinuddin, J. M. Shultz, R. Nakaoke and J. E. Morley, “Triglycerides Induce Leptin Resistance at the Blood-Brain Barrier,” Diabetes, Vol. 53, No. 5, 2004, pp. 1253-1260. doi:10.2337/diabetes.53.5.1253
[18] J. M. Harkins, N. Moustaid-Moussa, Y.-J. Chung, K. M. Penner, J. J. Pestka, C. M. North and K. J. Claycomb, “Expression of Interleukin-6 Is Greater in Preadipocytes than in Adipocytes of 3T3-L1 Cells and C57BL/6J and ob/ob Mice,” Journal of Nutrirtion, Vol. 134, No. 10, 2004, pp. 2673-2677.
[19] A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring and P. M. Ridker, “C-Reactive Protein, Interleukin-6, and Risk of Developing Type II Diabetes Mellitus,” Journal of American Medical Association, Vol. 286, No. 17, 2001, pp. 327-334. doi:10.1001/jama.286.3.327
[20] M. Fasshauer, J. Klein, U. Lossner and R. Paschke, “Interleukin (IL)-6 mRNA Expression Is Stimulated by Insulin, Isoproterenol, Tumour Necrosis Factor Alpha, Growth Hormone, and IL-6 in 3T3-L1 Adipocytes,” Hormone and Metabolic Research, Vol. 35, No. 3, 2003, pp. 147-152. doi:10.1055/s-2003-39075
[21] H. P. Kopp, C. W. Kopp, A. Festa, K. Krzyzanowska, S. Kriwanek, E. Minar, R. Roka and G. Schernthaner, “Impact of Weight Loss on Inflammatory Proteins and Their Association with the Insulin Resistance Syndrome in Morbidly Obese Patients,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 23, No. 6, 2003, pp. 1042-1047. doi:10.1161/01.ATV.0000073313.16135.21
[22] L. Roytblat, M. Rachinsky, A. Fisher, L. Greemberg, Y. Shapira, A. Douvdevani and S. Gelman, “Raised Interleukin-6 Levels in Obese Patients,” Obesity Research, Vol. 8, 9, 2000, pp. 673-675. doi:10.1038/oby.2000.86
[23] M. Laimer, C. F. Ebenbichler, S. Kaser, et al., “Markers of Chronic Inflammation and Obesity: A Prospective Study on the Reversibility of This Association in Middle-Aged Women Undergoing Weight Loss by Surgical Intervention,” International Journal of Obesity Related Metabolic Disorders, Vol. 26, No. 5, 2002, pp. 659-662. doi:10.1038/sj.ijo.0801970
[24] J. Li, F. H. Li and A. Zha, “Inflammation and Leptin,” Drug Discovery Today, Vol. 3, No. 3, 2006, pp. 387-393. doi:10.1016/j.ddmec.2006.09.003

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.